Hemostemix Inc (HEM) - Total Liabilities

Latest as of September 2025: CA$4.80 Million CAD ≈ $3.47 Million USD

Based on the latest financial reports, Hemostemix Inc (HEM) has total liabilities worth CA$4.80 Million CAD (≈ $3.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Hemostemix Inc to assess how effectively this company generates cash.

Hemostemix Inc - Total Liabilities Trend (2013–2024)

This chart illustrates how Hemostemix Inc's total liabilities have evolved over time, based on quarterly financial data. Check Hemostemix Inc (HEM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Hemostemix Inc Competitors by Total Liabilities

The table below lists competitors of Hemostemix Inc ranked by their total liabilities.

Company Country Total Liabilities
Avalon Holdings Corporation
NYSE MKT:AWX
USA $53.32 Million
Oceancash Pacific Bhd
KLSE:0049
Malaysia RM29.64 Million
Inter-Delta Tbk
JK:INTD
Indonesia Rp3.69 Billion
Garovaglio y Zorraquin S.A.
BA:GARO
Argentina AR$41.64 Billion
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
France €19.91 Million
LabGenomics Co. Ltd
KQ:084650
Korea ₩76.00 Billion
Axiom Properties Ltd
AU:AXI
Australia AU$6.62 Million
Pharmacielo Ltd
V:PCLO
Canada CA$23.57 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Hemostemix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hemostemix Inc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.54 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.58 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hemostemix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hemostemix Inc (2013–2024)

The table below shows the annual total liabilities of Hemostemix Inc from 2013 to 2024.

Year Total Liabilities Change
2024-12-31 CA$8.20 Million
≈ $5.93 Million
+6.65%
2023-12-31 CA$7.68 Million
≈ $5.56 Million
+6.23%
2022-12-31 CA$7.23 Million
≈ $5.23 Million
+23.73%
2021-12-31 CA$5.85 Million
≈ $4.23 Million
+70.87%
2020-12-31 CA$3.42 Million
≈ $2.48 Million
-17.54%
2019-12-31 CA$4.15 Million
≈ $3.00 Million
+253.31%
2018-12-31 CA$1.17 Million
≈ $849.58K
+152.68%
2017-12-31 CA$464.79K
≈ $336.22K
-87.40%
2016-12-31 CA$3.69 Million
≈ $2.67 Million
+492.45%
2015-12-31 CA$622.73K
≈ $450.47K
+12.87%
2014-12-31 CA$551.70K
≈ $399.09K
+127.05%
2013-12-31 CA$242.98K
≈ $175.77K
--

About Hemostemix Inc

V:HEM Canada Biotechnology
Market Cap
$8.18 Million
CA$11.31 Million CAD
Market Cap Rank
#27339 Global
#1183 in Canada
Share Price
CA$0.06
Change (1 day)
+0.00%
52-Week Range
CA$0.06 - CA$0.15
All Time High
CA$13.40
About

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more